Company Overview

Mitsubishi Tanabe Pharma Corporation

All figures are for the year ended March 2024 (FY2023)

Headquarters : 3-2-10, Dosho-machi, Chuo-ku, Osaka 541-8505, Japan

Representative : Akihiro Tsujimura, representative director

Hiroaki Ueno, representative director

Incorporated : December 13, 1933

Date of Merger : October 1, 2007

Capital Stock : 50 billion yen

Business Activities : Manufacture and sale of pharmaceuticals,

centered on ethical drugs

Number of Employees : 5,577 (consolidated),

3,044 (non-consolidated)



Mitsubishi Tanabe Pharma Corporation Website

Domestic Business Network



Tokyo Head Office

Sales bases

8 branches

A Research bases

3 offices

Subsidiary plants

2 sites

(Mitsubishi Tanabe Pharma Factory Ltd.)

Overseas Business Network

14 sites



Business Field

Founded in 1678, Mitsubishi Tanabe Pharma (MTPC) is one of the oldest pharmaceutical companies focused on the ethical drug business. Its headquarters stands in Dosho-machi, Osaka, the birthplace of the pharmaceutical industry in Japan. MTPC sets the MISSION of "Creating hope for all facing illness." To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidneys, and cancer.

MTPC will help to improve the quality of life of patients and their families around the world through the provision of pharmaceuticals.





Affected Area	Central Nervous System	Immuno-Inflammation	Diabetes and Kidney	Oncology
Mechanism	The brain processes and makes decisions on information from the entire body. Damage to it or the nerves of the spinal cord can lead to various symptoms including abnormalities in sensory and motor functions.	This disease occurs when something causes the immune system—which normally protects the body—to become abnormally activated and attack healthy cells and tissues.	High blood sugar and high blood pressure caused by diabetes can lead to various complications.	Masses of cells that occur due to gene mutations are known as malignant tumors (cancer) if they invade tissue or metastasize.
Targeted Indications	Amyotrophic Lateral Sclerosis (ALS) Tardive dyskinesia	Inflammatory bowel disease Erythropoietic protoporphyria	Type 2 diabetes Chronic kidney disease associated with Type 2 diabetes mellitus	Oncology for rare diseases
Key Markets	United States, Japan	United States, Japan	Japan	United States, Japan
Focus	Research and development Sales	Research and development Sales	Sales	Research and development